Loading...
Market
Story
Amgen's Imdelltra for Advanced Lung Cancer Wins Accelerated US Approval
May 16, 2024, 07:09 PM
Amgen has received US FDA accelerated approval for its new drug, Imdelltra, designed to treat adult patients with advanced small cell lung cancer. The approval, granted on May 16, 2024, marks a significant step in the fight against this particularly aggressive form of cancer. The drug, also known as tarlatamab, is a targeted immunotherapy aimed at patients whose condition has worsened despite chemotherapy.
View original story
Similar markets
Adopted in over 20 countries • 25%
Adopted in 10-20 countries • 25%
Adopted in less than 10 countries • 25%
Not adopted as standard treatment • 25%
EU only • 25%
UK only • 25%
Japan only • 25%
Multiple regions including EU, UK, and Japan • 25%
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
<10% • 25%
10%-25% • 25%
26%-50% • 25%
>50% • 25%
No further action • 33%
Additional warnings issued • 33%
Restriction on use broadened • 33%
Top performer • 33%
Average performer • 34%
Underperformer • 33%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%